---
title: How I treat transplant-eligible patients with myelofibrosis
date: '2023-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37647853/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230831181054&v=2.17.9.post6+86293ac
source: Blood
description: Despite approval of JAK inhibitors and novel agents for patients with
  myelofibrosis (MF), disease-modifying responses remain limited and hematopoietic
  stem cell transplantation (HSCT) remains the only potentially curative treatment
  option. Numbers of HSCT continue to increase worldwide for MF, but its inherent
  therapy-related morbidity and mortality limit its use for many patients. Furthermore,
  MF patients often present at older age, with cytopenia, splenomegaly, and severe
  bone marrow ...
disable_comments: true
---
Despite approval of JAK inhibitors and novel agents for patients with myelofibrosis (MF), disease-modifying responses remain limited and hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment option. Numbers of HSCT continue to increase worldwide for MF, but its inherent therapy-related morbidity and mortality limit its use for many patients. Furthermore, MF patients often present at older age, with cytopenia, splenomegaly, and severe bone marrow ...